Recent studies have been conducted in this setting [13-17], posing an equal balance between the advantages and disadvantages of SGLT2 inhibitors in patients with diabetes and CKD, to review the certainty of the updated evidence in this setting for the benefit of stakeholders, such as patients, healthcare professionals, and policy-makers. Here, SLC5A2 is linked to chronic kidney disease.